A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)
Study Number: GO41854
Study Summary:
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Status: Open
Open at Bloomington, Galesburg, Pekin, Peoria, and Peru
Study Coordinator(s)
- Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
- Jessica, 309-243-3615, jjones@illinoiscancercare.com
- Amanda , 309-243-3663, amullery@illinoiscancercare.com